Program Overview
This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, led by Dr. Mark Freedman, will first cover the topic of b-cells and anti-CD20 as therapeutic targets in the multiple sclerosis (MS) treatment landscape. Following, recent clinical trial data of anti-CD20 monoclonal antibody therapeutics to treat patients with relapsing multiple sclerosis will be reviewed, including key differences among both approved and emerging agents. Dr. Freedman will conclude with a summary of best practices for developing individualized treatment plans as well as practical considerations for switching disease modifying therapies to improve outcomes for patients with MS.
Target Audience
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Learning Objective
- Review the current science and clinical trial data for anti-CD20 monoclonal antibody therapeutics to treat patients with relapsing multiple sclerosis.
- Review effective measurements of disease activity and therapeutic efficacy which align with appropriate biomarkers and various pathologic processes that drive multiple sclerosis.
- Apply updated strategies and recent data to effectively switch therapies when there is opportunity to improve outcomes.
Agenda
I. Clinical Update for Anti-CD20 Monoclonal Antibody Therapeutics for Relapsing Multiple Sclerosis
II. Effective Measurements of Disease Activity and Therapeutic Efficacy that Align with Biomarkers and Pathologic Processes
III. Strategies to Apply Recent Data to Effectively Switch Therapies when there is Opportunity to Improve Outcomes
Faculty
Mark S. Freedman, MD, MSc
Professor of Medicine
University of Ottawa
Senior Scientist,
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Mark S. Freedman, MD, MSc | Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Atara Biotherapeutics, Inc.; Bayer AG; Biogen-Idec; Celestra Health; EMD Serono; Find Therapeutics, F. Hoffman La-Roche; Horizon Therapeutics plc; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis, AG; Neurogenesis, Inc.; Sandoz; Sanofi; Sentrex Health Solutions; SetPoint Medical; Teva Canada Innovation
Grant/Research Support: Sanofi-Genzyme Canada Speaker’s Bureau: EMD Serono; F. Hoffman La-Roche; Novartis AG |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Learners should only claim credit commensurate with the extent of their participation.
Financial Support
This activity has been supported by an independent educational grant from TG Therapeutics, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and TG Therapeutics, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
